TABLE 2.

Plasma glycerol, lactate, β-hydroxybutyrate, NEFA, and alanine levels during the basal period and the final 30 min of hyperinsulinemic-hypoglycemic clamp studies in type 1 diabetes before and after 6 weeks of fluoxetine or placebo administration

	Basal period	Final 30 min
Glycerol (μmol/l)
Before treatment	58 ± 7	65 ± 8
After fluoxetine	95 ± 25	110 ± 21*
Before treatment	67 ± 15	74 ± 15
After placebo	73 ± 11	80 ± 17
Lactate (mmol/l)
Before treatment	0.4 ± 0.04	0.75 ± 0.09
After fluoxetine	0.3 ± 0.02	0.83 ± 0.15
Before treatment	0.4 ± 0.04	0.75 ± 0.09
After placebo	0.4 ± 0.05	0.84 ± 0.00
β-Hydroxybutyrate (μmol/l)
Before treatment	0.099 ± 0.089	0.05 ± 0.03
After fluoxetine	0.046 ± 0.026	0.02 ± 0.01
Before treatment	0.07 ± 0.004	0.019 ± 0.002
After placebo	0.07 ± 0.005	0.02 ± 0.01
NEFA (μmol/l)
Before treatment	149 ± 38	93 ± 24
After fluoxetine	165 ± 41	182 ± 64*
Before treatment	131 ± 34	86 ± 22
After placebo	212 ± 37	91 ± 24
Alanine (μmol/l)
Before treatment	0.23 ± 0.02	0.22 ± 0.02
After fluoxetine	0.21 ± 0.02	0.21 ± 0.03
Before treatment	0.21 ± 0.02	0.20 ± 0.02
After placebo	0.24 ± 0.03	0.22 ± 0.02

Data are means ± SE. *Significantly increased responses during final 30 min of hypoglycemia after 6 weeks of fluoxetine administration (P < 0.05).